Ann: Strategic Review Update - Further Information, page-6

  1. 145 Posts.
    lightbulb Created with Sketch. 63
    This is a phenomenally bad deal for shareholders.

    The ANZ business is the only thing keeping MDR afloat & the access it provides to the Australian market is a crown jewel worth a huge amount to a global healthcare org. MDR management are giving it away for free.

    The US business is loss-making with significant debt, chances are in 3yrs (when any performance payment will be paid) MDR won’t exist. So ignore the performance payment - the ANZ business is getting sold for $35M.

    So the profitable ANZ business is valued at $35M, leaving the loss-making US business valued at $43M??? (ie. $78M mcap minus $35M). Lol.

    Sp is going to tank.

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
8.0¢
Change
-0.003(3.61%)
Mkt cap ! $50.02M
Open High Low Value Volume
8.4¢ 8.5¢ 7.9¢ $138.3K 1.717M

Buyers (Bids)

No. Vol. Price($)
1 120000 7.9¢
 

Sellers (Offers)

Price($) Vol. No.
8.2¢ 100000 1
View Market Depth
Last trade - 15.54pm 22/07/2025 (20 minute delay) ?
MDR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.